Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsClaudius WEILER, Stefan Johannes LEHNER
Life of this patent
Estimating the term…
Abstract
Systems and methods are described for treatment and/or prevention of a metabolic disorder and/or another medical condition in a patient (e.g., a feline) by administering to the patient a liquid pharmaceutical composition, preferably including one or more SGLT-2 inhibitor compound(s), via a delivery system that includes a syringe. The syringe includes features that facilitate easy, safe and effective doses of small volumetric amounts of the liquid pharmaceutical composition to the patient during administration.
Claims21
A system for administering a liquid pharmaceutical composition to a patient, the system comprising a syringe, wherein the syringe comprises:
- a barrel comprising a hollow elongated member including an open barrel forward end and an open barrel rear end, the hollow elongated member comprising:
- a first portion that extends from the open barrel forward end to a transition section disposed along the hollow elongated member, the first portion having a first cross-sectional dimension;
- and
- a second portion that extends from the transition section to the open barrel rear end, the second portion having a second cross-sectional dimension that is greater than the first cross-sectional dimension;
- and
- a plunger comprising an elongated member including a plunger forward end and a plunger rear end;
- wherein:
- the plunger and the barrel are dimensioned such that a portion of the plunger including the plunger forward end is insertable within the hollow elongated member of the barrel at the open barrel rear end, and the plunger is extendible within the barrel until the plunger forward end engages with an internal surface portion of the hollow elongated member at the barrel forward end;
- receipt of liquid pharmaceutical composition within the barrel of the syringe via the open barrel forward end is limited to a volume defined within the first portion of the barrel, wherein the volume is adjustable by adjusting a displacement of the plunger forward end away from the barrel forward end;
- and
- a surface wall section of the plunger includes indicia comprising a dosage scale that indicates the volume of the liquid pharmaceutical composition received within the first portion of the barrel based upon a corresponding displacement of the plunger forward end away from the barrel forward end.
A method of treatment and/or prevention of a metabolic disorder and/or another medical condition of a patient by administering a dosage of a liquid pharmaceutical composition comprising one or more SGLT-2 inhibitor compound(s) to the patient, the method comprising:
- providing a syringe and a container that includes the liquid pharmaceutical composition, the syringe comprising a barrel and a plunger, wherein:
- the barrel includes a hollow elongated member with an open barrel forward end and an open barrel rear end, a first portion that extends from the open barrel forward end to a transition section disposed along the hollow elongated member, the first portion having a first cross-sectional dimension, and a second portion that extends from the transition section to the open barrel rear end, the second portion having a second cross-sectional dimension that is greater than the first cross-sectional dimension;
- the plunger includes an elongated member and a dosage scale, the elongated member including a plunger forward end and a plunger rear end, and the dosage scale comprises a plurality of marks disposed on a surface wall section of the plunger and aligned in a direction that corresponds with a lengthwise dimension of the plunger;
- and
- the plunger and the barrel are dimensioned such that a portion of the plunger including the plunger forward end is insertable within the hollow elongated member of the barrel at the open barrel rear end, and the plunger is extendible within the barrel until the plunger forward end engages with an internal surface portion of the hollow elongated member at the barrel forward end;
- and
- withdrawing a desired dosage amount of the liquid pharmaceutical composition from the container into the first portion of the barrel of the syringe by displacing the plunger forward end a selected distance from the barrel forward end until a selected mark of the plurality of marks for the dosage scale aligns with an exterior surface of the barrel at the barrel rear end.
Dependencies are inferred from the claim text.